Find Suvorexant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

152 RELATED EXCIPIENT COMPANIES

247EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1030377-33-3, Mk-4305, Belsomra, Mk4305, Mk 4305, [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone
Molecular Formula
C23H23ClN6O2
Molecular Weight
450.9  g/mol
InChI Key
JYTNQNCOQXFQPK-MRXNPFEDSA-N
FDA UNII
081L192FO9

Suvorexant
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Suvorexant is an Orexin Receptor Antagonist. The mechanism of action of suvorexant is as an Orexin Receptor Antagonist, and P-Glycoprotein Inhibitor, and Cytochrome P450 3A Inhibitor.
1 2D Structure

Suvorexant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
2.1.2 InChI
InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
2.1.3 InChI Key
JYTNQNCOQXFQPK-MRXNPFEDSA-N
2.1.4 Canonical SMILES
CC1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
2.1.5 Isomeric SMILES
C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
2.2 Other Identifiers
2.2.1 UNII
081L192FO9
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

2. Belsomra

3. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-

4. Mk 4305

5. Mk-4305

6. Mk4305

2.3.2 Depositor-Supplied Synonyms

1. 1030377-33-3

2. Mk-4305

3. Belsomra

4. Mk4305

5. Mk 4305

6. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

7. Suvorexant (mk-4305)

8. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole

9. Chembl1083659

10. Chebi:82698

11. 081l192fo9

12. ((7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

13. Methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)-

14. (r)-(4-(5-chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone.

15. [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone

16. Suvorexant [usan:inn]

17. Dora-analogue

18. Unii-081l192fo9

19. Belsomra (tn)

20. Suv

21. Suvorexant [mi]

22. Suvorexant [inn]

23. Suvorexant [jan]

24. Suvorexant (jan/usan)

25. Suvorexant [usan]

26. Suvorexant; Mk 4305

27. Suvorexant [vandf]

28. Suvorexant [who-dd]

29. Amy337

30. Gtpl2890

31. Schembl1586289

32. Suvorexant [orange Book]

33. Dtxsid90145616

34. Ex-a211

35. Belsomra Component Suvorexant

36. Bdbm50318701

37. Mfcd22377755

38. Zinc49036447

39. Akos022185167

40. Cs-0614

41. Db09034

42. Suvorexant Component Of Belsomra

43. (4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

44. Ac-30276

45. As-74879

46. Hy-10807

47. Bcp0726000197

48. Ft-0697203

49. Sw219649-1

50. D10082

51. J-690010

52. Q7650517

53. Cas:1030377-33-3;mk-4305

54. 5-chloro-2-[(5r)-5-methyl-4-[5-methyl-2-(2h-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole Mk 4305

2.4 Create Date
2008-10-20
3 Chemical and Physical Properties
Molecular Weight 450.9 g/mol
Molecular Formula C23H23ClN6O2
XLogP34.9
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass450.1571017 g/mol
Monoisotopic Mass450.1571017 g/mol
Topological Polar Surface Area80.3 Ų
Heavy Atom Count32
Formal Charge0
Complexity664
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.


FDA Label


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Orexin Receptor Antagonists

Substances that bind to and inhibit the action of OREXIN RECEPTORS. Drugs in this class have been used as SLEEP AIDS, PHARMACEUTICAL. (See all compounds classified as Orexin Receptor Antagonists.)


Sleep Aids, Pharmaceutical

Drugs used to induce SLEEP, prevent SLEEPLESSNESS, or treat SLEEP INITIATION AND MAINTENANCE DISORDERS. (See all compounds classified as Sleep Aids, Pharmaceutical.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
SUVOREXANT
5.2.2 FDA UNII
081L192FO9
5.2.3 Pharmacological Classes
Orexin Receptor Antagonist [EPC]; Orexin Receptor Antagonists [MoA]; P-Glycoprotein Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]
5.3 ATC Code

N - Nervous system

N05 - Psycholeptics

N05C - Hypnotics and sedatives

N05CM - Other hypnotics and sedatives

N05CM19 - Suvorexant


5.4 Absorption, Distribution and Excretion

Absorption

Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%.


Route of Elimination

Approximately 66% is eliminated in feces and 23% is eliminated in urine.


Volume of Distribution

Mean volume of distribution is approximately 49 litres.


5.5 Metabolism/Metabolites

Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity.


5.6 Biological Half-Life

Mean half life is approximately 12 hours.


5.7 Mechanism of Action

Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677868200,"product":"PHARMACEUTICAL RAW MATERIAL: SUVOREXANT","address":"PLOT NO.C-24,INDUSTRIAL ESTATE, SANATHNAGAR CONTACT NO: 91966610210","city":"HYDERABAD","supplier":"MAITHRI LABORATORIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"CHARLOTTE, NC","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"100000","totalValueFC":"802.4","currency":"USD","unitRateINR":6600000,"date":"04-Mar-2023","totalValueINR":"66000","totalValueInUsd":"802.4","indian_port":"HYDERABAD AIR","hs_no":"29225090","bill_no":"8250448","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.C-24,INDUSTRIAL ESTATE, SANATHNAGAR CONTACT NO: 91966610210, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692815400,"product":"SUVOREXANT-MTM (5 MG)","address":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA","city":"Hyderabad","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.07","actualQuantity":"0.065","unit":"KGS","unitRateFc":"6737.8","totalValueFC":"434.6","currency":"USD","unitRateINR":553845.8953846154,"date":"24-Aug-2023","totalValueINR":"35999.9832","totalValueInUsd":"434.6","indian_port":"HYDERABAD ICD","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692815400,"product":"SUVOREXANT\/ DCO (5 MG)","address":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA","city":"Hyderabad","supplier":"HONOUR LAB LTD","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.07","actualQuantity":"0.065","unit":"KGS","unitRateFc":"6737.8","totalValueFC":"434.6","currency":"USD","unitRateINR":553845.8953846154,"date":"24-Aug-2023","totalValueINR":"35999.9832","totalValueInUsd":"434.6","indian_port":"HYDERABAD ICD","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"H.NO.8-3-166\/7\/1 HETERO HOUSEER RAGADDA, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703183400,"product":"SUVOREXANT (FORM-II) IN-HOUSE","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"25000","totalValueFC":"6186.7","currency":"USD","unitRateINR":2060000,"date":"22-Dec-2023","totalValueINR":"515000","totalValueInUsd":"6186.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6225788","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725993000,"product":"SUVOREXANT","address":"8-3-166\/182, A BLOCK, NORTH WING,,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"CAMBER PHARMACEUTICAL CO. ","customerCountry":"TAIWAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"22000","totalValueFC":"21794.5","currency":"USD","unitRateINR":1826408,"date":"11-Sep-2024","totalValueINR":"1826408","totalValueInUsd":"21794.5","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"3927015","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632681000,"product":"SUVOREXANT AMINE HCL(NOT RESTRICTED PER IATA SP A197)","address":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD","city":"HYDERABAD,A.P.","supplier":"MERCK GROUP","supplierCountry":"UNITED STATES","foreign_port":"NEW YORK","customer":"DIVIS LABORATORIES","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"3","unit":"GMS","unitRateFc":"75.2","totalValueFC":"228.2","currency":"USD","unitRateINR":"5595.3","date":"27-Sep-2021","totalValueINR":"16786","totalValueInUsd":"228.2","indian_port":"Vizag-DLL SEZ","hs_no":"29349990","bill_no":"1000973","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NEW YORK","supplierAddress":"A SUBSIDIARY OF MERCK & CO. INC 126 E. LICOLN AVENUE REHWAY NJ 07065 N J, , United States United States","customerAddress":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD"}]
27-Sep-2021
11-Sep-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Taste Masking

read-more
read-more

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty